Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4104455 | 1.00 | MEN1 (0.50) | MEN1KMT2ATSHRMAPK1THRB | |
| SCHEMBL64957 | 1.00 | MEN1 (0.50) | MEN1KMT2ATSHRMAPK1THRB | |
| SCHEMBL829630 | 1.00 | MEN1 (0.50) | MEN1KMT2ATSHRMAPK1THRB | |
| SCHEMBL9720673 | 1.00 | MEN1 (0.50) | MEN1KMT2ATSHRMAPK1THRB | |
| SCHEMBL829291 | 1.00 | MEN1 (0.50) | MEN1KMT2ATSHRMAPK1THRB | |
| SCHEMBL829172 | 1.00 | MEN1 (0.50) | MEN1KMT2ATSHRMAPK1THRB | |
| SCHEMBL830178 | 1.00 | MEN1 (0.50) | MEN1KMT2ATSHRMAPK1THRB | |
| SCHEMBL829553 | 1.00 | MEN1 (0.50) | MEN1KMT2ATSHRMAPK1THRB | |
| SCHEMBL679835 | 1.00 | MEN1 (0.50) | MEN1KMT2ATSHRMAPK1THRB | |
| SCHEMBL98075 | 1.00 | MEN1 (0.50) | MEN1KMT2ATSHRMAPK1THRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080275030-A1 | alkoxy-polyethylene glycol or (ethylene oxide)1-10 adduct of methanol, ethanol, propanol, isopropanol and cyclopropanol; benzodiazepine; midazolam as a liqid therapeutic agent; less irritation to mucosal membrane when administered through Mucosal; enhances solubility of drug | IKANO THERAPEUTICS, INC. (FORMERLY KNOWN AS "INTRANASAL THERAPEUTICS, INCORPORATED") | 2008-11-06 | — | — | US | claimed |
| US-12539313-B2 | Microbial removal | CAPRETTO EHF. (IS) | 2026-02-03 | — | — | US | disclosed |
| EP-3934753-B1 | MICROBIAL REMOVAL | CAPRETTO EHF (IS) | 2025-11-05 | — | — | EP | disclosed |
| US-20230107742-A1 | SYNERGISTIC EFFECTS, AUGMENTING ANTIMICROBAL EFFECTS OF LIPIDS | CAPRETTO EHF (IS) | 2023-04-06 | — | — | US | disclosed |
| US-11337949-B2 | Thermostable formulation of biologically active substances | CAPRETTO EHF. (IS) | 2022-05-24 | — | — | US | disclosed |
| US-20220152092-A1 | MICROBIAL REMOVAL | CAPRETTO EHF. (IS) | 2022-05-19 | — | — | US | disclosed |
| EP-3934753-A1 | MICROBIAL REMOVAL | Capretto EHF. (IS) | 2022-01-12 | — | — | EP | disclosed |
| EP-3471702-B1 | STABLE FORMULATION OF ANTIMICROBIAL LIPIDS | CAPRETTO EHF (IS) | 2021-12-29 | — | — | EP | disclosed |
| EP-3471541-B1 | SYNERGISTIC EFFECTS, AUGMENTING ANTIMICROBIAL EFFECTS OF LIPIDS | CAPRETTO EHF (IS) | 2021-05-05 | — | — | EP | disclosed |
| US-20190209511-A1 | THERMOSTABLE FORMULATION OF BIOLOGICALLY ACTIVE SUBSTANCES | CAPRETTO EHF. (IS) | 2019-07-11 | — | — | US | disclosed |
| EP-2121025-B1 | METHODS AND COMPOSITIONS FOR THE DELIVERY OF A THERAPEUTIC AGENT | HANANJA EHF (IS) | 2016-11-02 | — | — | EP | disclosed |
| US-20160158248-A1 | METHODS AND SYSTEMS FOR THE DELIVERY OF A THERAPEUTIC AGENT | HANANJA EHF | 2016-06-09 | — | — | US | disclosed |
| US-9289432-B2 | Methods and compositions for the delivery of a therapeutic agent | HANANJA EHF and UNIVERSITY OF ICELAND (IS) | 2016-03-22 | — | — | US | disclosed |
| US-20140323472-A1 | METHODS AND COMPOSITIONS FOR THE DELIVERY OF A THERAPEUTIC AGENT | HANANJA EHF (IS) | 2014-10-30 | — | — | US | disclosed |
| US-8809322-B2 | Methods and compositions for the delivery of a therapeutic agent | HANANJA EHF (IS) | 2014-08-19 | — | — | US | disclosed |
| US-20120264745-A1 | METHODS AND COMPOSITIONS FOR THE DELIVERY OF A THERAPEUTIC AGENT | UNIVERSITY OF ICELAND (IS) | 2012-10-18 | — | — | US | disclosed |
| US-8217033-B2 | Methods and compositions for the delivery of a therapeutic agent | HANANJA EHF (IS) | 2012-07-10 | — | — | US | disclosed |
| US-20110300091-A1 | TRANSLUCENT DEODORANT STICKS CONTAINING SOLUBILIZED 3,4,4'-TRICHLOROCARBANILIDE | THE DIAL CORPORATION (US) | 2011-12-08 | — | — | US | disclosed |
| US-20090227568-A1 | METHODS AND COMPOSITIONS FOR THE DELIVERY OF A THERAPEUTIC AGENT | HANANJA EHF (IS) | 2009-09-10 | — | — | US | disclosed |
| US-20080275030-A1 | alkoxy-polyethylene glycol or (ethylene oxide)1-10 adduct of methanol, ethanol, propanol, isopropanol and cyclopropanol; benzodiazepine; midazolam as a liqid therapeutic agent; less irritation to mucosal membrane when administered through Mucosal; enhances solubility of drug | IKANO THERAPEUTICS, INC. (FORMERLY KNOWN AS "INTRANASAL THERAPEUTICS, INCORPORATED") | 2008-11-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160158248-A1 | METHODS AND SYSTEMS FOR THE DELIVERY OF A THERAPEUTIC AGENT | TMEM205, NUP205, PIGS | MEN1 923/4885KMT2A 4084/4885TSHR 2469/4885 |
| US-20090227568-A1 | METHODS AND COMPOSITIONS FOR THE DELIVERY OF A THERAPEUTIC AGENT | TMEM205, NUP205, PIGS | MEN1 832/4885KMT2A 3911/4885TSHR 2833/4885 |
| US-20230107742-A1 | SYNERGISTIC EFFECTS, AUGMENTING ANTIMICROBAL EFFECTS OF LIPIDS | APOL1, MGLL, FABP2 | MEN1 957/4885KMT2A 4798/4885TSHR 2833/4885 |
| US-20120264745-A1 | METHODS AND COMPOSITIONS FOR THE DELIVERY OF A THERAPEUTIC AGENT | TMEM205, NUP205, PIGS | MEN1 832/4885KMT2A 3911/4885TSHR 2833/4885 |
| US-20140323472-A1 | METHODS AND COMPOSITIONS FOR THE DELIVERY OF A THERAPEUTIC AGENT | TMEM205, NUP205, PIGS | MEN1 832/4885KMT2A 3911/4885TSHR 2833/4885 |
| US-12539313-B2 | Microbial removal | CUTA, MIF, PCNA | MEN1 782/4885KMT2A 2838/4885TSHR 811/4885 |
| US-11337949-B2 | Thermostable formulation of biologically active substances | MGLL, DAGLA, DDOST | MEN1 1277/4885KMT2A 4668/4885TSHR 2220/4885 |
| US-20190209511-A1 | THERMOSTABLE FORMULATION OF BIOLOGICALLY ACTIVE SUBSTANCES | MGLL, DAGLA, DDOST | MEN1 1277/4885KMT2A 4668/4885TSHR 2220/4885 |
| US-20080275030-A1 | alkoxy-polyethylene glycol or (ethylene oxide)1-10 adduct of methanol, ethanol, propanol, isopropanol and cyclopropanol; benzodiazepine; midazolam as a liqid therapeutic agent; less irritation to mucosal membrane when administered through Mucosal; enhances solubility of drug | OPRD1, DRD2, DRD1 | MEN1 3906/4885KMT2A 2581/4885TSHR 2673/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.